General Notices

• Notice to Extend Eligibility for Submission of NIAMS K99/R00 Pathway to Independence Award Applications due to COVIDrelated Disruptions
  (NOT-AR-21-029)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of NIDA's Participation in NOT-MD-22-006 "Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities"
  (NOT-DA-22-002)
  National Institute on Drug Abuse
  

• Notice of Information Regarding Eligibility of Schools of Engineering for Research Enhancement Award Program (REAP) Funding Opportunity Announcements
  (NOT-GM-22-028)
  National Institute of General Medical Sciences
  

• Notice of Information on Cloud Computing and High-Throughput Computing Resources for Collaborative Research in Computational Neuroscience (CRCNS) Grantees
  (NOT-MH-22-120)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  

• Notice of Pre-Application Webinar for PAR-22-088, Biomedical Research Facilities (C06 CT NA) and PAR-21-363, Limited Competition: Development and Renovation of Housing, Breeding, and Research Spaces for Existing NIH-supported NHP Colonies (C06 CT NA)
  (NOT-OD-22-060)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  

• Notice to Add a Receipt Date for RFA-OH-22-001: Occupational Safety and Health Education and Research Centers
  (NOT-OH-22-002)
  National Institute for Occupational Safety and Health
  

• Notice to Add a Receipt Date for RFA-OH-22-002: Centers for Agricultural Safety and Health
  (NOT-OH-22-003)
  National Institute for Occupational Safety and Health
  

• Request for Information (RFI): Seeking Input from Multi-Cancer Early Detection Test Developers on Readiness for Participation in an NCI-Sponsored Clinical Utility Randomized Controlled Screening Trial
  (NOT-CA-22-033)
  National Cancer Institute
  

Notice of Changes to Funding Opportunities

• Notice of Change to Key Dates for RFA-AG-23-003 "Resources to Promote Coordination and Collaboration across Deeply Phenotyped Longitudinal Behavioral and Social Studies of Aging (U24 Clinical Trial Not Allowed)"
  (NOT-AG-22-010)
  National Institute on Aging
  

• Notice of Early Expiration of "PAR-20-095 Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed)"
  (NOT-AG-22-013)
  National Institute on Aging
  

• Notice of Early Expiration of RFA-AI-21-021, Enhancement or Sustainment of Data Science Tools for Infectious and Immune-Mediated diseases (U24 Clinical Trial Not Allowed)"
  (NOT-AI-22-027)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Change to Award Information for RFA-DK-21-020, Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)
  (NOT-DK-22-010)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Award Information for RFA-DK-21-036, Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) - Biostatistics Research Center (U01 Clinical Trial Not Allowed)
  (NOT-DK-22-011)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Termination of PAR-22-070, "NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)"
  (NOT-EY-22-003)
  National Eye Institute
  

• Notice to Extend the Application Due Date for RFA-FD-22-006 "Conformance with the Egg Regulatory Program Standards (U2F) Clinical Trial Not Allowed"
  (NOT-FD-22-005)
  Food and Drug Administration
  

• Notice of Change to Description of NIGMS Interest in the S10 Funding Opportunity Announcements PAR-22-079, PAR-22-080, and PAR-22-081
  (NOT-GM-22-029)
  National Institute of General Medical Sciences
  

• Notice of Change to Application Due Date for PAR-21-281, "Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 - Clinical Trials Not Allowed)"
  (NOT-OD-22-059)
  NIH Basic Behavioral and Social Science Opportunity Network
  

• Notice of Early Termination of PAR-22-057 "Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)"
  (NOT-TR-22-015)
  National Center for Advancing Translational Sciences
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Alcohol Health Services Research (R01 Clinical Trial Optional)
  (NOT-AA-22-004)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Alcohol Health Services Research (R34 Clinical Trial Optional)
  (NOT-AA-22-005)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Alcohol Treatment and Recovery Research (R01 Clinical Trial Required)
  (NOT-AA-22-006)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Alcohol Treatment and Recovery Research (R34 Clinical Trial Required)
  (NOT-AA-22-007)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)
  (NOT-EB-22-002)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
  (NOT-TR-22-014)
  National Center for Advancing Translational Sciences
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Dental and Craniofacial Research
  National Institute of General Medical Sciences
  National Institute on Minority Health and Health Disparities
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations with the NCI- supported PDX Development and Trial Centers Research Network (PDXNet)
  (NOT-CA-22-039)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and Addiction
  (NOT-DA-23-001)
  National Institute on Drug Abuse
  Office of Disease Prevention
  

• Notice of Special Interest (NOSI): Administrative Supplements to Enhance Laboratory Safety Curriculum and a Culture of Safety in Biomedical Research Training Environments
  (NOT-GM-22-010)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Promote Safe and Inclusive Biomedical Research Training Environments
  (NOT-GM-22-011)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Modules to Enhance Undergraduate Biomedical Research Training
  (NOT-GM-22-012)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Administrative Supplements to Enhance Program Evaluation Capacity
  (NOT-GM-22-013)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Activities to Enhance Mentoring in the Research Training Environment
  (NOT-GM-22-014)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Administrative Supplements for Curriculum or Training Activities to Enhance Wellness and Resiliency in the Training Environment
  (NOT-GM-22-015)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Administrative Supplements for Equipment Purchases for Select NIGMS-Funded Awards
  (NOT-GM-22-017)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs for SARS-CoV-2 Surveillance Studies
  (NOT-GM-22-026)
  National Institute of General Medical Sciences
  

• RESCINDED - Notice of Special Interest (NOSI): Enhancing Research on Deciphering Mechanisms of COVID-19-Associated Coagulopathy
  (NOT-HL-23-003)
  National Heart, Lung, and Blood Institute
  

• Notice of Special Interest (NOSI): COVID-19 Pandemic Mental Health Research
  (NOT-MH-22-100)
  National Institute of Mental Health
  

Funding Opportunities

• Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
  (PAR-22-058)
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Neurological Disorders and Stroke
  Office of Research on Women's Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
  (PAR-22-075)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): January 07, 2025
  
  

• Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
  (PAR-22-083)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
  (PAR-22-084)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
  (PAR-22-099)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)
  (PAR-22-102)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional)
  (PAR-22-103)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Nonhuman Primate Transplantation Tolerance Cooperative Study Group (U01 Clinical Trial Not Allowed)
  (RFA-AI-22-002)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 13, 2022
  
  

• Nonhuman Primate Transplantation Tolerance Cooperative Study Group (U19 Clinical Trial Not Allowed)
  (RFA-AI-22-003)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 13, 2022
  
  

• HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
  (RFA-DE-22-011)
  National Institute of Dental and Craniofacial Research
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): March 31, 2022
  
  

• Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional)
  (RFA-DK-22-005)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): May 17, 2022
  
  

• Revolutionizing Innovative, Visionary Environmental Health Research (RIVER) (R35 Clinical Trial Optional)
  (RFA-ES-22-002)
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): June 09, 2022
  
  

• Federal and State Integration Activities to Advance Cooperation and Regulatory Standards Among Animal Food Safety Regulatory Programs (U2F) Clinical Trials Not Allowed
  (RFA-FD-22-009)
  Food and Drug Administration
  Application Receipt Date(s): April 4, 2022, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Revision Applications - Development and Maintenance of the Animal Feed Regulatory Program Standards Flexible Funding Model Compliance and Enforcement Expansion Supplement (U18) [Clinical Trials Not Allowed]
  (RFA-FD-22-010)
  Food and Drug Administration
  Application Receipt Date(s): April 4, 2022, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Revision Applications - Manufactured Food Flexible Funding Model Compliance and Enforcement Expansion Supplement (U18) [Clinical Trials Not Allowed
  (RFA-FD-22-019)
  Food and Drug Administration
  Application Receipt Date(s): April 04, 2022
  
  

• Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3/UH3 Clinical Trial Optional)
  (RFA-HD-22-024)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Office of Research on Women's Health
  Application Receipt Date(s): April 18, 2022
  
  

• Genome Research Experiences to Attract Talented Undergraduates into Genomic Fields to Enhance Diversity (R25 Clinical Trial Not Allowed)
  (RFA-HG-22-004)
  National Human Genome Research Institute
  Application Receipt Date(s): July 01, 2023
  
  

• ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (U01 Clinical Trial Not Allowed)
  (RFA-HL-23-001)
  National Heart, Lung, and Blood Institute
  National Institute of General Medical Sciences
  Application Receipt Date(s): June 17, 2022
  
  

• ARDS, Pneumonia, and Sepsis Phenotyping Consortium Coordinating Center (U01 Clinical Trial Not Allowed)
  (RFA-HL-23-002)
  National Heart, Lung, and Blood Institute
  National Institute of General Medical Sciences
  Application Receipt Date(s): June 17, 2022
  
  

• Stimulating Access to Research in Residency (StARR) (R38)
  (RFA-HL-23-006)
  National Heart, Lung, and Blood Institute
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 16, 2024
  
  

• Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 Clinical Trial Optional)
  (RFA-MD-22-007)
  National Institute on Minority Health and Health Disparities
  National Institute of Mental Health
  Office of Disease Prevention
  Application Receipt Date(s): March 28, 2022
  
  

• Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Data Resource and Administrative Coordination Center (U24 Clinical Trial Not Allowed)
  (RFA-MH-22-110)
  National Institute of Mental Health
  Application Receipt Date(s): June 10, 2022
  
  

• Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Assay and Data Generation Centers (RM1 Clinical Trial Not Allowed)
  (RFA-MH-22-111)
  National Institute of Mental Health
  Application Receipt Date(s): June 10, 2022
  
  

• BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative (R01 Clinical Trial Not Allowed)
  (RFA-MH-22-145)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Emergency Award HEAL Initiative: Optimizing Existing Evidence-Based Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)
  (RFA-MH-22-175)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): March 18, 2022
  
  

• Emergency Award HEAL Initiative: Developing and Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional)
  (RFA-MH-22-176)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): March 18, 2022
  
  

• HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required)
  (RFA-NS-22-037)
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  Office of Research on Women's Health
  Application Receipt Date(s): March 22, 2022
  
  

• Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
  (RFA-TR-22-011)
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): April 16, 2023
  
  

• Emergency Awards: HEAL Initiative-Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Research Network (ERN) (U24 Clinical Trial Not Allowed)
  (RFA-TR-22-012)
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): March 15, 2022
  
  

• Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
  (RFA-TR-22-013)
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): April 18, 2023